Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Phosphatase
    (6)
  • Glucokinase
    (3)
  • transporter
    (2)
  • Autophagy
    (1)
  • Endogenous Metabolite
    (1)
  • FABP
    (1)
  • HIV Protease
    (1)
  • IGF-1R
    (1)
  • Microtubule Associated
    (1)
  • Others
    (9)
Filter
Search Result
Results for "

glucose uptake inhibitor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    29
    TargetMol | Inhibitors_Agonists
  • Natural Products
    3
    TargetMol | Natural_Products
  • Isotope Products
    2
    TargetMol | Isotope_Products
SIRT6-IN-5
SIRT6 inhibitor5, SIRT6 IN 5, SIRT6 inhibitor-5, SIRT6 inhibitor 5
T24793891002-11-2In house
SIRT6-IN-5(SIRT6 inhibitor 5) is a potent and selective SIRT6 inhibitor with an IC50 value of 34 μM.SIRT6-IN-5 is immunosuppressive and chemo-sensitizing, increases H3K9 acetylation and glucose uptake in cultured cells, and reduces T-cell proliferation.
  • Inquiry Price
6-8 weeks
Size
QTY
PTP1B-IN-22
T6789386109-60-6In house
PTP1B-IN-22 is a protein tyrosine phosphatase 1B (PTP1B) inhibitor that inhibits glucose uptake in skeletal muscle L6 myotubes.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Oxfendazole
RS-8858
T071453716-50-0
Oxfendazole (RS-8858), a broad spectrum benzimidazole anthelmintic, protects livestock against roundworm, strongyles and pinworms.
  • Inquiry Price
Size
QTY
Bis(maltolato)oxovanadium(IV)
BMOV, Bis maltolato oxovanadium,Bis(maltolato)oxovanadium (IV),bis maltolato oxo vanadium, Bis(maltolato)oxovanadium (IV)
T2227638213-69-3
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive, and orally active pan-PTP (protein tyrosine phosphatases) inhibitor with insulin-mimicking effects and anti-diabetic properties. BMOV is a potent insulin sensitizer and has been shown to improve cardiac dysfunctions in diabetic models. BMOV inhibits HCPTPA, PTP1B, HPTPβ, and SHP2 with IC50s of 126 nM, 109 nM, 26 nM, and 201 nM, respectively [1][2].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Stearic acid
Octadecanoic acid, Cetylacetic acid
T2P292357-11-4
1. Stearic acid (Cetylacetic acid) can reduce metastatic tumor burden. 2. Stearic acid leads to dramatically reduced visceral fat likely by causing the apoptosis of preadipocytes. 3. Stearic acid and its derivatives have been used as gelators in food and pharmaceutical gel formulations. 4. Stearic acid is a potent phosphatase 1B inhibitor, possibly causing an enhancement in the insulin receptor signaling to stimulate glucose uptake into adipocytes. 5. Stearic acid has the potential to increase dry matter intake and yields of milk and milk components, without affecting conversion of feed to milk, body condition score, or body weight.
  • Inquiry Price
Size
QTY
Cichoric Acid
Dicaffeoyltartaric acid, Chicoric Acid
TL00066537-80-0
Cichoric Acid (Dicaffeoyltartaric acid) is a potent inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the replication in tissues. It also a class of cannabinomimetics with CB2 receptor-dependent and independent.
  • Inquiry Price
Size
QTY
MID-1
T8773312608-54-1
MID-1 is an inhibitor of MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction. It disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
hydrocotarnine
T9352550-10-7
hydrocotarnine is an inhibitor of Cbl.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AS1949490
T143271203680-76-5
AS1949490 activated glucose metabolism via up-regulation of GLUT1 gene in L6 myotubes[1][2]. AS1949490 is a potent and selective SHIP-2 (SH2 domain-containing inositol 5′ phosphatase 2) inhibitor, with an IC50 of 620 nM.
  • Inquiry Price
Size
QTY
(Rac)-Glutipyran
T201827350993-69-0
(Rac)-Glutipyran is a broad-spectrum GLUT inhibitor targeting both GLUT1 and GLUT3. This compound inhibits glucose uptake and significantly impedes the growth of various cancer cells, particularly demonstrating substantial inhibition of PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM).
  • Inquiry Price
10-14 weeks
Size
QTY
LXQ-87
T2035222524718-73-6
LXQ-87 is an orally administered, non-competitive inhibitor of PTP1B with an IC50 of 1.061 μM, demonstrating hypoglycemic activity. It alleviates insulin resistance and enhances cellular glucose uptake, making it useful for type 2 diabetes research.
  • Inquiry Price
Size
QTY
α-Amylase-IN-12
T2055051799667-33-6
α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor with an IC50 of 0.15 mM, functioning through a mixed inhibition mode. It exhibits an IC50 of 9.40 mM against α-glucosidase. This compound enhances glucose uptake in yeast cells and demonstrates significant anti-glycation activity at high concentrations. α-Amylase-IN-12 is applicable for diabetes research.
  • Inquiry Price
10-14 weeks
Size
QTY
luseogliflozin
TS-71, TS71, TS-071, TS071, TS 71, TS 071
T21399898537-18-3
Luseogliflozin, a potent and competitive inhibitor of sodium-dependent glucose cotransporter 2 (SGLT2), competitively inhibits human SGLT2-mediated glucose uptake with a Ki value of 1.10 nM.
  • Inquiry Price
Size
QTY
3PO
T2222318550-98-6
3PO is a small-molecule inhibitor of PFKFB3 (IC50: 22.9 μM), inhibiting the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50: 1.4-24 μM). It suppresses glucose uptake, and decreases the intracellular concentration
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AS1938909
AS 1938909,AS-1938909
T251111243155-40-9
AS1938909 is a SHIP2 inhibitor that works by increasing Akt phosphorylation, glucose consumption, and glucose uptake in L6 myotubes, specifically upregulating the GLUT1 gene.
  • Inquiry Price
6-8 weeks
Size
QTY
6-Benzylthioinosine
6-BT,6Benzylthioinosine,6-Bn-thioinosine
T263956165-03-3
6-Benzylthioinosine, a broad-spectrum metabolic inhibitor, inhibits glucose uptake, decreases glycolysis and ATP concentration with minimal changes in ROS and mitochondrial respiration.
  • Inquiry Price
Size
QTY
AZD6482 (S-isomer)
AZD-6482,AZD 6482,AZD6482 (S),AZD6482
T302611173900-37-2
AZD6482 (S-isomer) is a potent, selective, ATP-competitive PI3Kβ inhibitor (IC(50) 0.01 μm), which can inhibit insulin-induced in vitro glucose uptake by human adipocytes (IC(50) is 4.4 μm).
  • Inquiry Price
6-8 weeks
Size
QTY
MitoPQ
MitoParaquat
T334121821370-28-8
MitoPQ (MitoParaquat) is a mitochondria-targeted small molecule compound that selectively enhances mitochondrial superoxide and hydrogen peroxide levels and inhibits insulin-stimulated glucose uptake and translocation of glucose transport protein 4 (GLUT4) to the plasma membrane in adipocytes and myotubes.MitoPQ can be used to MitoPQ can be used to study mitochondrial oxidative stress and regulated GLUT4 transporter.
  • Inquiry Price
Size
QTY
SW157765
T40413332063-87-3
SW157765 is a selective glucose transporter GLUT8 (SLC2A8) inhibitor, a prodrug of many compounds, that selectively inhibits the uptake of fluorescent 2-deoxyglucose (2DG) in SW157765-sensitive cells in a dose-dependent manner, and can be used for the study of lung cancer.
  • Inquiry Price
7-10 days
Size
QTY
BMS-309403
T4534300657-03-8
BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.
  • Inquiry Price
Size
QTY
PF-06761281
PF06761281
T605471854061-19-0
PF-06761281 (Compound 4a) is a potent and partially selective sodium-coupled citrate transporter protein (NaCT SLC13A5) inhibitor with IC50 values of 0.51, 13.2, and 14.1 µM for NaCT, NaDC, and NaDC, respectively, and has the advantage of being orally active, reducing hepatic and renal uptake of citrate and plasma glucose concentration for metabolic diseases.
    7-10 days
    Inquiry
    gsk-3β inhibitor 6
    T61804
    GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β with an IC50 value of 24.4 μM, significantly enhancing hepatocyte glucose uptake (38%). This compound holds great potential for studying diseases such as diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1].
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    gsk-3β inhibitor 7
    T63866
    GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM) that acts by inserting into the ATP-binding pocket of GSK-3β and forming hydrogen bonds. It exhibits a high rate of glucose uptake by hepatocytes (83.5%) and can be used to study various diseases such as cancer, diabetes, inflammation, Alzheimer's disease, and bipolar disorder.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    Gliclazide-d4
    T719811185039-30-8
    Gliclazide-d4 is intended for use as an internal standard for the quantification of gliclazide by GC- or LC-MS. Gliclazide is a sulfonylurea and an inhibitor of pancreatic β-cell ATP-sensitive potassium (KATP) channels. It is selective for pancreatic β-cell over cardiac and arterial smooth muscle cell KATP channels. Gliclazide (5 μM) increases insulin-induced glucose uptake and glucose transporter 4 (GLUT4) translocation to the plasma membrane in a differentiated 3T3L1 adipocyte model of insulin resistance induced by hydrogen peroxide. Gliclazide (5 and 10 μg ml) reduces LDL oxidation by human aortic smooth muscle cells (HASMCs), decreasing TBARS content and 8-isoprostane levels. It also decreases oxidized LDL-induced HASMC proliferation and monocyte adhesion when used at concentrations ranging from 1 to 10 μg ml. Gliclazide (5 mg kg) reduces serum glucose levels and increases glucose uptake by isolated rat hindquarters in a model of diabetes induced by streptozotocin (STZ).
    • Inquiry Price
    7-10 days
    Size
    QTY